Compare Vanguard Total Stock Market Index Fund ETF (VTI) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Total Stock Market Index Fund ETF vs State Street SPDR S&P Biotech ETF — how do they compare? Vanguard Total Stock Market Index Fund ETF trades at $381.94 (market cap $2.30T), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: Vanguard Total Stock Market Index Fund ETF is far larger — about 227.5× State Street SPDR S&P Biotech ETF's market cap, and Vanguard Total Stock Market Index Fund ETF is trading nearer its 52-week high, State Street SPDR S&P Biotech ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Vanguard Total Stock Market Index Fund ETF for 131 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| VTI | XBI | |
|---|---|---|
Market Cap | $2.30T | $10.11B |
Volume | 2,982,924 | 12,903,266 |
52-Week High | $384.30 | $169.55 |
52-Week Low | $311.68 | $104.99 |
Typical Hold Time | 131 Days | 38 Days |
Sector | — | Broad Market / Factor |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VTI trades at $379.56, down 0.39% on the day, with a bullish technical signal driven by moving averages. The ETF provides broad U.S. equity exposure, though key valuation and profitability ratios are not publicly disclosed for the fund itself. Recent news highlights its role in diversified portfolios and long-term growth potential.
The outlook for VTI remains positive given its low-cost, diversified structure and historical performance. Risks include market concentration in top holdings and broader economic volatility. Analyst sentiment is generally favorable for long-term investors seeking total market exposure.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Vanguard Total Stock Market Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the index, which represents approximately 100% of the investable US stock market and includes large-, mid-, small-, and micro-cap stocks. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.
Read more on VTI →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
